Aldeyra Therapeutics resubmits an NDA for reproxalap to treat the signs and symptoms of dry eye disease.
FDA warns Chinas Zhejiang Huahai Pharmaceutical Co. about CGMP violations in its production of finished drugs.
The latest semiannual report issued by the HHS Office of Inspector General raises questions about specific FDA accelerated drug approvals.
A ProPublica investigative report details how a secret small group of FDA officials has approved exemptions for products from overseas factories that ...
Roche moves prasinezumab into a Phase 3 trial after two mid‑stage trials and their open‑label extensions hinted at a disease‑slowing...
Milestone Pharmaceuticals submits its response to a March-issued FDA complete response letter on the companys NDA for irregular heart beat drug Cardam...
Zyno Medical recalls certain Z-800 infusion pumps because they were released to customers with incorrect software versions.
Qalitex Laboratories issues an alert to dietary supplement and wellness product sellers on Amazon about a growing overlap between FDAs enforcement and...
